Research & Development

Research and development forms an integral part of Pharmagen. Our research and development manifestation is our belief in quality improvements and innovation aimed at adding value for all stakeholders. Our long term relationship with multinational and quality conscious customers testifies to Pharmagen's commitment to find newer and better ways to manufacture our products.

Our team of experienced PhDs and researchers, backed by high quality infrastructure, are concentrating on continuous existing process improvement and development of new range of bulk chemicals.

Product(s) in pipeline:

Product Name


Therapeutic Class

Clarithromycin BP & USP Antibiotic
Esomeprazole Magnesium Trihydrate BP & USP Proton pump inhibitor, Anti-Ulcerant
Atorvastatin Calcium Trihydrate BP & USP HMG Co-A reductase inhibitor; lipid-regulating drug
Amlodipine Besilate BP & USP Calcium channel blocker
Montelukast Sodium BP Leukotriene CysLT1 Receptor Antagonist
Moxifloxacin BP & USP Anti-inflammatory
Sitaglyptin IFS Anti-Diabetic
Linaglyptin IFS Anti-Diabetic
Aloglyptin IFS Anti-Diabetic
Vildaglyptin IFS Anti-Diabetic
Azithromycin BP & USP Antibiotic
Naproxen Sodium BP & USP Nonnarcotic Analgesic, Antipyretic, Anti-inflammatory
Ledipasvir IFS Antiviral
Declatasvir IFS Antiviral